Assessing Differential Needs Among University Freshmen: A Comparison Among Racial/Ethnic Subgroups

Author(s):  
Lydia Yuriko Minatoya ◽  
William E. Sedlacek
Circulation ◽  
2012 ◽  
Vol 125 (suppl_10) ◽  
Author(s):  
Sukyung Chung ◽  
Eric C Wong ◽  
Kristen M Azar ◽  
Beinan Zhao ◽  
Diane Lauderdale ◽  
...  

Introduction Early screening for diabetes is the most cost effective way to prevent complications. Diabetes screening rates in a clinical population are unknown. There are well-known racial/ethnic differences in diabetes prevalence, with some Asian Americans racial/ethnic subgroups (e.g. Asian Indian and Filipino) having higher rates than Non Hispanic White (NHW) populations, and this may result in higher rates of diabetes screening for Asian Americans. Hypothesis We hypothesized that, after taking into account other risks factors suggested by national guidelines, Asian Americans may have higher preventive screening rates, given known higher risk for diabetes. Methods We used the electronic health records data from a large multi-specialty, mixed-payer, outpatient, group- practice organization in Northern California, to examine an observational prospective dataset during 1/1/2007-09/30/2010. Active primary care patients who were 35 years or older, not pregnant, identified as Asian (Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese) or non-Hispanic white (NHW), and were free from diabetes at baseline were included (N=110,477). Screening was defined as fasting glucose, oral glucose tolerance test, or HgBA1C. Racial/ethnic differences in screening rates were initially examined with age-sex standardization. We then estimated a Cox proportional hazard model, which adjusted for diabetes clinical risk factors (including age, sex, BMI, high blood pressure, high LDL, low HDL), family history of diabetes, insurance coverage, and frequency of primary care visits. Results Standardized preventive screening rates were higher for all Asian racial/ethnic subgroups (ranging from 82.2%: Japanese to 88.7%: Filipino) than NHW (78.6%)( P<0.05 ). The results were consistent in the fully adjusted Cox model where all the Asian racial/ethnic subgroups, except for Japanese (not significant), were more likely to be screened than NHWs (HR=Asian Indian: 1.29, Chinese: 1.20, Filipino: 1.22, Korean: 1.13, Vietnamese: 1.24; all P<0.01 ). Most clinical risk factors were significant positive predictors of screening, including age, female, high blood pressure, high LDL, low HDL, and family history of diabetes(all P<0.01 ). Conclusions Screening rates for diabetes in an insured, ambulatory care population is generally high (∼80%). Clinical risk factors and Asian race/ethnicity are predictors of appropriate diabetes screening.


2011 ◽  
Vol 14 (4) ◽  
pp. 344-365 ◽  
Author(s):  
Meghan S. Stroshine ◽  
Steven G. Brandl

According to tokenism theory, “tokens” (those who comprise less than 15% of a group’s total) are expected to experience a variety of hardships in the workplace, such as feelings of heightened visibility, isolation, and limited opportunities for advancement. In the policing literature, most previous studies have defined tokenism narrowly in terms of gender. The current research extends prior research by examining tokenism as a function of gender and race, with an examination of racial/ethnic subgroups. Particular attention is paid to Latino officers as this study represents the first known study of tokenism and Latino police officers. Quantitative analyses reveal that, for the most part, token police officers do experience the effects of tokenism as predicted by tokenism theory. Although all minorities experienced some level of tokenism, Black males and Black females experienced greater levels of tokenism than Latino officers, suggesting that race is a stronger predictor of tokenism than gender.


2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Dipanjan Banerjee ◽  
Eric C. Wong ◽  
Jessica Shin ◽  
Stephen P. Fortmann ◽  
Latha Palaniappan

Background. Lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD) in Non-Hispanic Whites (NHW). There are known racial/ethnic differences in Lp(a) levels, and the association of Lp(a) with CVD outcomes has not been examined in Asian Americans in the USA.Objective. We hypothesized that Lp(a) levels would differ in Asian Indians and Chinese Americans when compared to NHW and that the relationship between Lp(a) and CVD outcomes would be different in these Asian racial/ethnic subgroups when compared to NHW.Methods. We studied the outpatient electronic health records of 2022 NHW, 295 Asian Indians, and 151 Chinese adults age≥18 y in Northern California in whom Lp(a) levels were assessed during routine clinical care from 2001 to 2008, excluding those who had received prescriptions for niacin (14.6%). Nonparametric methods were used to compare median Lp(a) levels. Significance was assessed at theP<.0001level to account for multiple comparisons. CVD outcomes were defined as ischemic heart disease (IHD) (265 events), stroke (122), or peripheral vascular disease (PVD) (87). We used logistic regression to determine the relationship between Lp(a) and CVD outcomes.Results. Both Asian Indians (36 nmol/L) and NHW (29 nmol/L) had higher median Lp(a) levels than Chinese (22 nmol/L,P≤.0001andP=.0032). When stratified by sex, the differences in median Lp(a) between these groups persisted in the 1761 men (AI v CH:P=.001, NHW v CH:P=.0018) but were not statistically significant in the 1130 women (AI v CH:P=.0402, NHW v CH:P=.0761). Asian Indians (OR=2.0) and Chinese (OR=4.8) exhibited a trend towards greater risk of IHD with high Lp(a) levels than NHW (OR=1.4), but no relationship was statistically significant.Conclusion. Asian Indian and NHW men have higher Lp(a) values than Chinese men, with a trend toward, similar associations in women. High Lp(a) may be more strongly associated with IHD in Asian Indians and Chinese, although we did not have a sufficient number of outcomes to confirm this. Further studies should strive to elucidate the relationship between Lp(a) levels, CVD, and race/ethnicity among Asian subgroups in the USA.


2003 ◽  
Vol 163 (5) ◽  
pp. 632 ◽  
Author(s):  
Limin X. Clegg ◽  
Frederick P. Li ◽  
Benjamin F. Hankey ◽  
Kenneth Chu ◽  
Brenda K. Edwards

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Justin T Parizo ◽  
Fatima Rodriguez ◽  
Alexander T Sandhu ◽  
Manisha Desai ◽  
Kiran K Khush

Introduction: It is unknown if there are disparities in the transition from heart failure (HF) to listing for heart transplant (HT), although there are clear disparities in this transition in the transplant of other organs. Methods: We used CDC WONDER data and SRTR transplant data to identify county-level age-adjusted HF mortality and number of candidates listed for HT from 2006 to 2018 among racial/ ethnic subgroups. We determined rates of candidate listing and age-adjusted HF deaths (AAHFD) per 100,000 persons on aggregate and by racial/ ethnic subgroups. County-level demographic, socioeconomic, cardiovascular disease risk, and healthcare factors from public databases were used in multivariate models to determine factor groups explaining variation in candidates listed per AAHFD. Results: The median (IQR) candidates per AAHFD for the aggregated county cohort was 1.3 (0.75-2.0; 2558 counties reported data), the non-Hispanic white (NHW) county cohort was 1.5 (0.88-2.2; 2426 counties), the non-Hispanic black (NHB) county cohort was 1.1 (0.64-1.6; 860 counties), and the Hispanic county cohort was 1.1 (0.67-1.8; 254 counties) (p-value <0.001). The lowest candidates per AAHFD were in the South for NHW (median 1.3) and NHB (0.97), but in the West for Hispanic (0.84). Multivariate models with all county-level variables, explained (R 2 ) 28.7%, 38.7%, and 57.3% of variation in candidates listed per AAHFD for NHW, NHB, and Hispanic cohorts, respectively. Socioeconomic factors (R 2 0.14), healthcare factors (R 2 0.21), and cardiovascular disease risk factors (R 2 0.18), respectively, explained the greatest variation in models using variable subgroups. Conclusions: When age-adjusted rates of HF mortality by race/ ethnicity group is considered, HT candidate listing for NHB and Hispanic candidates is 27% lower than for NHW. County-level factors that explain variation in HT listing vary by racial/ ethnicity group, and explain more variation in NHB and Hispanic cohorts.


Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Gerardo Gamino ◽  
Justin T Parizo ◽  
David Scheinker ◽  
Fatima Rodriguez

Introduction: Racial/ethnic diversity in clinical trials is essential to ensure that our evidence base reflects the population. We assessed the extent of reporting and representation of race/ethnicity in heart failure (HF) clinical trials referenced in the contemporary ACC/AHA HF guidelines. Methods: All randomized trials referenced in the 2013 ACC/AHA Heart Failure Guidelines and the 2017 Focused Update were included. The prevalence of reporting of race/ethnicity, the proportions of racial/ethnic subgroups enrolled, and subgroup analysis based on intervention type - pharmacologic, device, and other - were evaluated. Results: We identified 256 trials (545 233 subjects) published between 1950 and 2018. Among these, only 95 reported any race/ethnicity (37.1%), 94 reported white race (36.7%), 58 reported black race (22.7%), 16 reported Hispanic ethnicity (6.3%), and 23 reported Asian race (9.0%). In trials reporting white, black, Hispanic, and Asian race/ethnicity respectively, 76.4% (n = 299 153 of 299872) of patients were white, 11.7% (n = 25 274 of 215 905) of patients were black, 11.2% (n = of 8863 of 79 097) of patients were Hispanic, and 10.5% (n = 14925 of 141 504) of patients were Asian. Comparison of trial population proportions with US Census population demonstrates over-representation of white subjects, and under-representation of Hispanic and black subjects (Figure). Stratification by intervention type demonstrated that no device trials referenced in the guidelines report black or Asian race, and just one reported Hispanic race. Conclusions: Trials that dictate clinical care of patients with HF through informing contemporary ACC/AHA HF guidelines under-represent black and Hispanic populations. Additionally, 2/3rds of trials fail to report any race/ ethnicity at all. There is a need for guideline and practice-informing clinical trials to adequately represent all populations, and to provide clinicians the data they need to assess generalizability.


2011 ◽  
Vol 21 (8) ◽  
pp. 608-614 ◽  
Author(s):  
Ariel T. Holland ◽  
Eric C. Wong ◽  
Diane S. Lauderdale ◽  
Latha P. Palaniappan

Sign in / Sign up

Export Citation Format

Share Document